Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects
- Registration Number
- NCT00777530
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
The purpose of this study is to assess the safety and tolerability of ascending single oral doses of bosutinib administered with multiple doses of ketoconazole and to provide the pharmacokinetic profile of bosutinib when administered with multiple doses of ketoconazole and with food in healthy adult subjects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 Bosutinib (SKI-606) -
- Primary Outcome Measures
Name Time Method Safety based on adverse events monitoring, physical examinations, vital sign evaluations, 12-lead ECGs and routine laboratory tests. 5 weeks
- Secondary Outcome Measures
Name Time Method Blood samples 5 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of bosutinib in targeting BCR-ABL and Src family kinases in leukemia?
How does bosutinib compare to imatinib and dasatinib in terms of efficacy and safety for CML treatment?
Which biomarkers are associated with response to bosutinib in patients with chronic myeloid leukemia?
What are the potential adverse events and management strategies for bosutinib in phase 1 trials?
What is the role of CYP3A4 inhibition by ketoconazole in bosutinib's pharmacokinetics and drug interactions?